Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $70.61, for a total value of $155,342.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Monday, May 12th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $72.06, for a total value of $158,532.00.
• On Thursday, April 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $70.22, for a total value of $154,484.00.

Corcept Therapeutics Stock Performance

NASDAQ CORT traded down $1.12 on Friday, hitting $70.06. 1,008,383 shares of the stock traded hands, compared to its average volume of 1,140,717. The business's fifty day moving average is $71.48 and its two-hundred day moving average is $64.38. Corcept Therapeutics Incorporated has a 12 month low of $28.04 and a 12 month high of $117.33. The firm has a market capitalization of $7.43 billion, a price-to-earnings ratio of 55.60 and a beta of 0.19. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, hitting analysts' consensus estimates of $0.17. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $157.21 million during the quarter, compared to analyst estimates of $177.93 million. During the same period last year, the company earned $0.25 earnings per share. The business's revenue for the quarter was up 7.1% on a year-over-year basis. As a group, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Corcept Therapeutics

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Corcept Therapeutics by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company's stock worth $509,726,000 after acquiring an additional 109,294 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Corcept Therapeutics by 3.7% in the first quarter. Parallel Advisors LLC now owns 3,972,416 shares of the biotechnology company's stock worth $453,729,000 after acquiring an additional 142,784 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Corcept Therapeutics by 2.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,136,510 shares of the biotechnology company's stock worth $243,708,000 after acquiring an additional 57,942 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Corcept Therapeutics by 4.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company's stock worth $82,889,000 after acquiring an additional 64,321 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Corcept Therapeutics by 12.5% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,376,881 shares of the biotechnology company's stock worth $69,381,000 after acquiring an additional 153,100 shares during the period. 93.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on CORT. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Wall Street Zen lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, May 14th. HC Wainwright reduced their price objective on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Truist Financial set a $135.00 price objective on Corcept Therapeutics in a report on Tuesday, May 6th. Finally, Piper Sandler increased their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a report on Thursday, April 3rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $138.25.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.